TCE
AvenCell’s platform of T cell engaging bispecific antibody (TCE) is characterized by high-binding affinity to tumor antigens and lower affinity to the CD3 antigen on effector T cells, preventing T cell auto-activation in pre-clinical models.
The use of fully humanized antibodies reduces the risk of immunogenicity even in case of chronic dosing.
AvenCell’s platform of T cell engaging bispecific antibody (TCE) is characterized by high binding affinity to tumor antigens and lower affinity to the CD3 antigen on effector T cells, preventing T cell auto-activation in pre-clinical models. The use of fully humanized antibodies reduces the risk of immunogenicity even in case of chronic dosing. Our lead clinical-stage TCE asset AVC-001 is globally partnered with Bristol-Myers Squibb. AVC-001 is a TCE with binding specificities to CD3 and PSCA, currently in early clinical development in multiple PSCA-positive advanced solid tumors (see https://clinicaltrials.gov/ct2/show/NCT03927573).
Our Patents
As patents are critical to AvenCell’s business, we have filed a wide range of patent applications globally to protect our innovative technologies and products. The patent family is continuously extended.
